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Sir,
We appreciate the interest of O’Donnell et al in our report on
temsirolimus in neuroendocrine cancers (NEC). They suggest that
based on the tumour control rate observed in our study,
temsirolimus may have activity in advanced NEC ‘beyond the
natural course of disease’. We completely agree with this
observation. In fact, as discussed in our manuscript, at the end
of stage I in this two-staged trial, we had amended the protocol
despite not meeting the originally set criteria, and proceeded to
stage II based on the observed decrease in tumour progression rate
and clinical benefit in some patients. We concluded the manu-
script by declaring that temsirolimus appears to have modest
activity in NEC, and advocating the development of combination
studies with this agent.
We also share the enthusiasm of O’Donnell et al for efficient
clinical trial designs to evaluate the activity of new molecularly
targeted compounds. However, we would respectfully disagree
with their statement that this is best achieved by abandoning
single-arm phase II studies.
Phase II trials play a pivotal screening role in the drug
development process (Mariani and Marubini, 2000; Taylor et al,
2006). Given that patient and financial resources are precious, and
there is a pressing need to rapidly bring true advances to the clinic,
efficient phase II trial designs that reliably retain promising agents
while quickly discard inactive ones are critical. This is particular
true when we have such a wide range of novel agents undergoing
evaluation. Traditional single-arm phase II trials that focused
solely on response might underestimate the cytostatic activity of
some molecular targeted agents; however including tumour
control within the primary end point can overcome this limitation,
as can referencing the tumour control rates to other studies of less-
active agents in the same population (as was done by O’Donnell
et al in coming to the conclusion that temsirolimus does have
some activity against NEC based upon our study results). In our
study, after the accrual of 37 patients over 18 months, we were able
to draw useful conclusions about the antitumour activity of
temsirolimus in NEC, thus reaffirming that single-arm phase II
trials remain a good choice for promptly determining if a drug
should advance to further development.
The randomised discontinuation design has been proposed as
an alternate more complex option to evaluate the efficacy of
cytostatic drugs (Ratain et al, 2006). This design represents an
appealing alternative with some limitations (Freidlin and Simon,
2005). These studies tend to be much larger than other phase II
designs; as an example, 368 patients were entered on a clinical trial
of carboxyaminoimidazole in renal cell carcinoma that used the
randomised discontinuation design and concluded that the drug
was inactive (Stadler et al, 2005). Given the multitude of interesting
options for renal cell cancer under evaluation, a design that
requires over 350 patients to conclude that a drug is inactive lacks
the efficiency we are all seeking. As an interesting comparison, two
multikinase inhibitors, sorafenib and sunitinib, have now been
approved for advanced renal cell cancers. The phase II develop-
ment of sorafenib utilised the randomised discontinuation design
and enrolled 202 patients, 36% of patients had tumour shrinkage
of X25% and 32% achieved stable disease at 12 weeks (Ratain
et al, 2006). The phase II development of sunitinib utilised a single-
arm phase II design and enrolled 106 patients, 34% of patients had
partial responses by RECIST criteria and 29% achieved stable
disease for X3 months (Motzer et al, 2006). Both trials led to
further phase III evaluations due to the promising activity detected
by their respective phase II designs.
Lastly, O’Donnell et al draw analogies between renal cell
carcinoma and NEC. One needs to be cautious in extrapolating
from an experience in a tumour that has a different biology,
natural history and response to therapy.
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